Danaher stock
DHRNYSEDanaher Corporation, HealthcareISIN US2358511028
66Score 66 out of 100, Neutral
Price and trend
82 / 100
Price history
+9.0% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 17% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 56).
The price is 2.8% below its 52-week high. Largest decline in 20 years: 46% (December 2007 to March 2009).
Chart figures for advanced users
- SMA 50$221.62
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$200.89
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)56
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$161.91
- The lowest closing price of the last twelve months.
- Resistance$242.05
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Danaher Corporation belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $165.55B, is number 2 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $24.57B (up 2.9% year on year) and earnings of $3.61B (down 7.3%).
- For fiscal 2026, analysts expect on average revenue of $26.26B (up 6.9%) and adjusted earnings per share of $8.59 (up 10.1%).
Show more
- MEQIRI Score 66 out of 100 (Neutral): rank 195 of 714 in Healthcare, median 53.
- The P/E is 38.4 (Medical (Diagnostics & Research) median 33.7, own median of recent years 34.6).
- Our model puts fair value at $191.09, with the price 23% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for over 33 years.Capital allocation 59
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 85
- Earnings turn into cashFree cash flow 132% of earnings over the last 12 months.Fundamentals 85
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and technical analysis, while growth and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- calm price action
- price near its 52-week high
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $146.99 and expensive above $272.98 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $175.43 (cash-flow model) and $206.75 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 9.7%. At 10.7% the fair value would be $177.71, at 8.7% it would be $210.03.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (33.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 25 Sep 2026, revenue rose 5.5% on the twelve months before. Up to 2021 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 5.5% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 61%, operating 21%, net 15%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 27 Jan 2027in 76 days
- Last reported
- 21 Oct 2026EPS reported $2.11 (expected $1.92)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $8.59+1.0%
- Revenue
- $26.26B−0.4%
- Earnings per share
- $9.31+0.2%
- Revenue
- $28.27B−0.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −10.9%2026 adjusted EPS guidance raised to $8.45 to $8.60, up from $8.35 to $8.55.
“Additionally, given our second quarter earnings beat and the earlier than anticipated completion of the Masimo acquisition, we're raising our full-year adjusted diluted net EPS guidance to a range of $8.45-$8.60, versus our previous range of $8.35-$8.55.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 21 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $26.11M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Danaher
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 66
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- Thermo Fisher ScientificTMO $265.92B69
- WuXi AppTec603259.SS $67.65B84
- IDEXX LaboratoriesIDXX $55.35B79
- Agilent TechnologiesA $49.89B77
- NateraNTRA $46.38B43
- WatersWAT $46.24B56
- IQVIA HoldingsIQV $45.24B67
- Mettler-Toledo InternationalMTD $35.04B76
ETFs that hold Danaher
Held by 116 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| VanEck Morningstar US ESG Wide Moat UCITS ETFGMVM | 2.58% | 0.49% | €368.7M |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 2.17% | 0.12% | €1.34B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 2.14% | 0.15% | €3.27B |
Show 5 more
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 2.11% | 0.15% | €592.11M |
| Harbor Health Care UCITS ETF AccW311 | 1.87% | 0.89% | €11.61M |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.87% | 0.49% | €318.39M |
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 1.57% | 0.25% | €4.18B |
| iShares Healthcare Innovation UCITS ETF2B78 | 1.41% | 0.40% | €1.49B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 29 Feb 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.